IC
IC7.F ICU Medical Inc
- Market cap
- EUR 4.00B
- P/E
- 77.7x
- P/B
- 2.04x
- ROE
- 4.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IC7.F undervalued?
Graham numberIC7.F trades 165.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ICU Medical Inc fundamental analysis
No fundamental analysis for ICU Medical Inc yet.
ICU Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ICU Medical Inc
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-co…
Full company profileICU Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ICU Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 379M | 1.29B | 1.40B | 1.27B | 1.27B | 1.32B | 2.28B | 2.26B | 2.38B | 2.23B | 2.19B |
| Gross Profit | 201M | 426M | 570M | 472M | 461M | 491M | 698M | 740M | 825M | 822M | 901M |
| Operating Income | 99.0M | 70.9M | 189M | 146M | 135M | 141M | -3.57M | 47.8M | 97.4M | 109M | 199M |
| EBITDA | - | 120M | 97.8M | 200M | 194M | 124M | 187M | 253M | 260M | 298M | 346M |
| Net Income | 63.1M | 68.6M | 28.8M | 101M | 86.9M | 103M | -74.3M | -29.7M | -118M | 732K | 101M |
| EPS | - | 3.40 | 1.41 | 4.87 | 4.13 | 4.34 | -3.10 | -1.23 | -4.81 | 0.03 | 4.06 |
| Balance Sheet | |||||||||||
| Total Assets | 705M | 1.50B | 1.59B | 1.69B | 1.76B | 1.88B | 4.52B | 4.38B | 4.20B | 4.05B | 3.94B |
| Total Liabilities | 44.5M | 299M | 322M | 315M | 261M | 265M | 2.43B | 2.26B | 2.24B | 1.93B | 1.75B |
| Shareholders' Equity | 660M | 1.20B | 1.26B | 1.38B | 1.50B | 1.62B | 2.09B | 2.12B | 1.97B | 2.12B | 2.19B |
| Cash & Short-term Investments | 445M | 290M | 345M | 269M | 396M | 553M | 209M | 254M | 309M | 308M | 302M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 89.9M | 154M | 160M | 102M | 223M | 268M | -62.1M | 166M | 204M | 180M | 292M |
| Capital Expenditure | 24.6M | 74.5M | 92.7M | 97.3M | 92.0M | 68.5M | 90.3M | 93.7M | 90.2M | 97.0M | 68.3M |
| Free Cash Flow | - | 74.7M | 59.4M | -4.12M | 122M | 186M | -161M | 72.5M | 114M | 82.8M | 223M |
| Ratios | |||||||||||
| ROE | 9.6% | 5.7% | 2.3% | 7.3% | 5.8% | 6.4% | -3.6% | -1.4% | -6.0% | 0.0% | 4.6% |
| ROA | 9.0% | 4.6% | 1.8% | 6.0% | 4.9% | 5.5% | -1.6% | -0.7% | -2.8% | 0.0% | 2.6% |
| Net Profit Margin | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% | 4.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ICU Medical Inc dividends
ICU Medical Inc has not paid dividends in the last 9 fiscal years.
Who owns ICU Medical Inc
- Insiders 1.76%
- Institutions 98.25%
- Public & others 0.00%
- Shares outstanding 25.0M
- Free float 24.6M
ICU Medical Inc company profile
- Company name
- ICU Medical Inc
- Ticker
- IC7.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,000
- Fiscal year end
- December
- Address
- 951 Calle Amanecer, San Clemente, CA, United States, 92673
- Phone
- 949 366 2183
- Website
- icumed.com
About ICU Medical Inc
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
ICU Medical Inc management
7- Mr. Vivek JainCEO & Chairman of the Board · born 1972
- Mr. Daniel WoolsonPresident · born 1977
- Mr. Brian Michael BonnellCFO & Treasurer · born 1974
- Mr. Christian B. VoigtlanderChief Operating Officer · born 1968
- Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer · born 1975
- Ben SousaChief Information Officer
- Olivia BarrallVice President of Human Resources